Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.

<h4>Background</h4>Current tools for the diagnosis of tuberculosis pleural effusions are sub-optimal. Data about the value of new diagnostic technologies are limited, particularly, in high burden settings. Preliminary case control studies have identified IFN-gamma-inducible-10 kDa protei...

Full description

Bibliographic Details
Main Authors: Keertan Dheda, Richard N Van-Zyl Smit, Leonardo A Sechi, Motasim Badri, Richard Meldau, Gregory Symons, Hoosein Khalfey, Igshaan Carr, Alice Maredza, Rodney Dawson, Helen Wainright, Andrew Whitelaw, Eric D Bateman, Alimuddin Zumla
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19277111/pdf/?tool=EBI
id doaj-baa4d0fe7fd24b198853321c1f77e24b
record_format Article
spelling doaj-baa4d0fe7fd24b198853321c1f77e24b2021-03-03T22:41:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032009-01-0143e468910.1371/journal.pone.0004689Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.Keertan DhedaRichard N Van-Zyl SmitLeonardo A SechiMotasim BadriRichard MeldauGregory SymonsHoosein KhalfeyIgshaan CarrAlice MaredzaRodney DawsonHelen WainrightAndrew WhitelawEric D BatemanAlimuddin Zumla<h4>Background</h4>Current tools for the diagnosis of tuberculosis pleural effusions are sub-optimal. Data about the value of new diagnostic technologies are limited, particularly, in high burden settings. Preliminary case control studies have identified IFN-gamma-inducible-10 kDa protein (IP-10) as a promising diagnostic marker; however, its diagnostic utility in a day-to-day clinical setting is unclear. Detection of LAM antigen has not previously been evaluated in pleural fluid.<h4>Methods</h4>We investigated the comparative diagnostic utility of established (adenosine deaminase [ADA]), more recent (standardized nucleic-acid-amplification-test [NAAT]) and newer technologies (a standardized LAM mycobacterial antigen-detection assay and IP-10 levels) for the evaluation of pleural effusions in 78 consecutively recruited South African tuberculosis suspects. All consenting participants underwent pleural biopsy unless contra-indicated or refused. The reference standard comprised culture positivity for M. tuberculosis or histology suggestive of tuberculosis.<h4>Principal findings</h4>Of 74 evaluable subjects 48, 7 and 19 had definite, probable and non-TB, respectively. IP-10 levels were significantly higher in TB vs non-TB participants (p<0.0001). The respective outcomes [sensitivity, specificity, PPV, NPV %] for the different diagnostic modalities were: ADA at the 30 IU/L cut-point [96; 69; 90; 85], NAAT [6; 93; 67; 28], IP-10 at the 28,170 pg/ml ROC-derived cut-point [80; 82; 91; 64], and IP-10 at the 4035 pg/ml cut-point [100; 53; 83; 100]. Thus IP-10, using the ROC-derived cut-point, missed approximately 20% of TB cases and mis-diagnosed approximately 20% of non-TB cases. By contrast, when a lower cut-point was used a negative test excluded TB. The NAAT had a poor sensitivity but high specificity. LAM antigen-detection was not diagnostically useful.<h4>Conclusion</h4>Although IP-10, like ADA, has sub-optimal specificity, it may be a clinically useful rule-out test for tuberculous pleural effusions. Larger multi-centric studies are now required to confirm our findings.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19277111/pdf/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Keertan Dheda
Richard N Van-Zyl Smit
Leonardo A Sechi
Motasim Badri
Richard Meldau
Gregory Symons
Hoosein Khalfey
Igshaan Carr
Alice Maredza
Rodney Dawson
Helen Wainright
Andrew Whitelaw
Eric D Bateman
Alimuddin Zumla
spellingShingle Keertan Dheda
Richard N Van-Zyl Smit
Leonardo A Sechi
Motasim Badri
Richard Meldau
Gregory Symons
Hoosein Khalfey
Igshaan Carr
Alice Maredza
Rodney Dawson
Helen Wainright
Andrew Whitelaw
Eric D Bateman
Alimuddin Zumla
Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.
PLoS ONE
author_facet Keertan Dheda
Richard N Van-Zyl Smit
Leonardo A Sechi
Motasim Badri
Richard Meldau
Gregory Symons
Hoosein Khalfey
Igshaan Carr
Alice Maredza
Rodney Dawson
Helen Wainright
Andrew Whitelaw
Eric D Bateman
Alimuddin Zumla
author_sort Keertan Dheda
title Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.
title_short Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.
title_full Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.
title_fullStr Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.
title_full_unstemmed Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.
title_sort clinical diagnostic utility of ip-10 and lam antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2009-01-01
description <h4>Background</h4>Current tools for the diagnosis of tuberculosis pleural effusions are sub-optimal. Data about the value of new diagnostic technologies are limited, particularly, in high burden settings. Preliminary case control studies have identified IFN-gamma-inducible-10 kDa protein (IP-10) as a promising diagnostic marker; however, its diagnostic utility in a day-to-day clinical setting is unclear. Detection of LAM antigen has not previously been evaluated in pleural fluid.<h4>Methods</h4>We investigated the comparative diagnostic utility of established (adenosine deaminase [ADA]), more recent (standardized nucleic-acid-amplification-test [NAAT]) and newer technologies (a standardized LAM mycobacterial antigen-detection assay and IP-10 levels) for the evaluation of pleural effusions in 78 consecutively recruited South African tuberculosis suspects. All consenting participants underwent pleural biopsy unless contra-indicated or refused. The reference standard comprised culture positivity for M. tuberculosis or histology suggestive of tuberculosis.<h4>Principal findings</h4>Of 74 evaluable subjects 48, 7 and 19 had definite, probable and non-TB, respectively. IP-10 levels were significantly higher in TB vs non-TB participants (p<0.0001). The respective outcomes [sensitivity, specificity, PPV, NPV %] for the different diagnostic modalities were: ADA at the 30 IU/L cut-point [96; 69; 90; 85], NAAT [6; 93; 67; 28], IP-10 at the 28,170 pg/ml ROC-derived cut-point [80; 82; 91; 64], and IP-10 at the 4035 pg/ml cut-point [100; 53; 83; 100]. Thus IP-10, using the ROC-derived cut-point, missed approximately 20% of TB cases and mis-diagnosed approximately 20% of non-TB cases. By contrast, when a lower cut-point was used a negative test excluded TB. The NAAT had a poor sensitivity but high specificity. LAM antigen-detection was not diagnostically useful.<h4>Conclusion</h4>Although IP-10, like ADA, has sub-optimal specificity, it may be a clinically useful rule-out test for tuberculous pleural effusions. Larger multi-centric studies are now required to confirm our findings.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19277111/pdf/?tool=EBI
work_keys_str_mv AT keertandheda clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT richardnvanzylsmit clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT leonardoasechi clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT motasimbadri clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT richardmeldau clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT gregorysymons clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT hooseinkhalfey clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT igshaancarr clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT alicemaredza clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT rodneydawson clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT helenwainright clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT andrewwhitelaw clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT ericdbateman clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
AT alimuddinzumla clinicaldiagnosticutilityofip10andlamantigenlevelsforthediagnosisoftuberculouspleuraleffusionsinahighburdensetting
_version_ 1714812289356398592